% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{KropfSanchen:302860,
      author       = {C. Kropf-Sanchen$^*$ and A. Rasokat and P. Christopoulos
                      and C. Wenzel and T. Wehler and M. Rost and J. Kulhavy and
                      N. Reinmuth and C. Schulz and M. Scheffler and J. Wolf and
                      R. Büttner and S. Merkelbach-Bruse and M. Thomas and A.
                      Stenzinger and M. Schütz and A. Bräuninger and M. Demes
                      and H.-D. Hummel and N. Pfarr and N. T. Gaisa and J. Rawluk
                      and E. Berezucki and K. T. Lutz and S. Galda and H. Jacobi
                      and M. Collienne$^*$ and M. Janning$^*$ and T. Brummer$^*$
                      and S. Loges$^*$},
      collaboration = {n. L. Cancer},
      title        = {{T}reatment outcome of {NSCLC} patients with
                      {BRAF}non-{V}600{E} mutations: a retrospective, multicentre
                      analysis within the national {N}etwork {G}enomic {M}edicine
                      (n{NGM}) {L}ung {C}ancer in {G}ermany.},
      journal      = {ESMO open},
      volume       = {10},
      number       = {8},
      issn         = {2059-7029},
      address      = {[London]},
      publisher    = {Elsevier},
      reportid     = {DKFZ-2025-01400},
      pages        = {105124},
      year         = {2025},
      note         = {#EA:A420#LA:A420#},
      abstract     = {Non-small-cell lung cancer patients with BRAFV600E
                      mutations benefit from targeted and (chemo-)immune therapy.
                      However, treatment of BRAFnon-V600E mutations poses
                      substantial challenges due to biological heterogeneity,
                      different clinicogenomic features and limited therapy
                      outcome data.We conducted a retrospective analysis of
                      BRAFnon-V600E mutation patients in the national Network
                      Genomic Medicine Lung Cancer, assessing treatment outcomes
                      upon targeted and (chemo-)immune therapy. Additionally, we
                      evaluated mitogen-activated protein kinase
                      (MEK)/extracellular-signal-regulated kinase (ERK) activation
                      potential of selected, previously not characterized
                      mutations in vitro.Fifty-three patients with 11 different
                      BRAFnon-V600E mutations undergoing targeted and/or
                      (chemo-)immune therapy were identified. Patients with class
                      I mutations achieved the longest progression-free survival
                      (PFS) under targeted therapy [median PFS (mPFS) 9.8 months],
                      whereas chemotherapy and chemoimmunotherapy led to an mPFS
                      of 35 and 27 months, respectively. In patients with class II
                      mutations, targeted therapy led to an mPFS of 6.3 months
                      while chemotherapy, chemoimmunotherapy and immunotherapy
                      resulted in an mPFS of 3.5, 3.7 and 3.6 months,
                      respectively. Preclinical characterization demonstrated MEK
                      phosphorylation potential and hence actionability of BRAF
                      class II mutations G469A, G469R, G469V and BRAF K601.
                      Patients exhibiting class III mutations did not respond to
                      targeted therapy (mPFS 2.6 months), but showed responses to
                      chemotherapy (mPFS 4.2 months), chemoimmunotherapy (mPFS
                      10.9 months) and immunotherapy (mPFS 7 months).Patients with
                      activating BRAFnon-V600E mutations respond to BRAF/MEK
                      inhibitor or (chemo-)immunotherapy, while those with
                      non-activating mutations do not benefit from targeted
                      therapy, but may benefit from (chemo-)immune therapy.
                      Correlating preclinical activation assays with clinical
                      outcomes can guide treatment decisions for patients with
                      BRAFnon-V600E mutations, facilitating personalized treatment
                      approaches.},
      keywords     = {BRAF(non-V600E) (Other) / MEK/ERK activation potential
                      (Other) / non-small-cell lung cancer (Other) / targeted
                      therapy (Other)},
      cin          = {A420 / FR01},
      ddc          = {610},
      cid          = {I:(DE-He78)A420-20160331 / I:(DE-He78)FR01-20160331},
      pnm          = {311 - Zellbiologie und Tumorbiologie (POF4-311)},
      pid          = {G:(DE-HGF)POF4-311},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40664146},
      doi          = {10.1016/j.esmoop.2025.105124},
      url          = {https://inrepo02.dkfz.de/record/302860},
}